The DLC1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the DLC1 tumor suppressor gene in the near-haploid HAP1 cell line. This product provides a heterogeneous pool of cells harboring CRISPR/Cas9-mediated gene disruption events, offering a robust loss-of-function model without the clonal selection often required for monoclonal lines. By ablating DLC1 expression across a polyclonal background, researchers can interrogate the collective impact of diverse knockout alleles on cellular phenotypes, minimizing clonal artefact and yielding biologically representative data for downstream applications.
The HAP1 host cell line is derived from a male patient with chronic myeloid leukemia in blast crisis and displays a near-haploid karyotype, which simplifies genetic manipulation and facilitates homozygous gene disruption. These adherent, fibroblastoid cells retain the BCR-ABL1 fusion oncogene characteristic of CML, providing a disease-relevant context for studying tumor suppressor loss in a leukemic background. Their haploid nature reduces genetic redundancy, making them a preferred model for CRISPR-based screens and mechanistic studies where unambiguous genotype?Cphenotype correlations are critical.
DLC1 encodes a Rho GTPase-activating protein (RhoGAP) that negatively regulates Rho family GTPases, including RhoA, RhoC, and Cdc42, by accelerating GTP hydrolysis to maintain them in an inactive GDP-bound state. This enzymatic activity is regulated by upstream signals such as AKT-mediated phosphorylation and promoter CpG methylation, and is modulated by transcription factors like p53 and E2F1, as well as by microRNAs miR-141 and miR-200a. DLC1 directly interacts with focal adhesion scaffold proteins tensin-1, tensin-2, and tensin-3, and associates with talin and FAK, thereby coupling RhoGAP function to integrin-mediated adhesion dynamics. Consequently, DLC1 suppresses downstream effectors including ROCK, MLC2 phosphorylation, and actin stress fiber formation, and restrains nuclear translocation of the transcriptional co-activators YAP/TAZ, which are critical for cell proliferation and survival.
In the HAP1 model, disruption of DLC1 is expected to result in constitutive activation of RhoA, RhoC, and Cdc42, leading to enhanced ROCK-dependent actomyosin contractility, increased cell migration and invasion, and dysregulated focal adhesion turnover. The loss of DLC1 may also relieve inhibition of YAP/TAZ, promoting transcriptional programs that drive proliferation and inhibit apoptosis. Given the BCR-ABL1-driven oncogenic signaling in HAP1 cells, the combined loss of DLC1 could synergize with leukemogenic pathways such as PI3K/AKT, making this model particularly relevant for investigating mechanisms of disease progression and therapeutic resistance in hematological malignancies and solid tumors.
These polyclonal knockout cells are ideally suited for a wide spectrum of research applications, including dissecting tumor suppressor mechanisms, studying Rho GTPase signaling cascades, and evaluating cell migration and invasion using Boyden chamber assays. They facilitate co-immunoprecipitation experiments to probe DLC1-tensin interactions, immunofluorescence staining for F-actin and YAP/TAZ localization, and Rho GTPase activity pull-down assays. The model is valuable for drug discovery efforts targeting hepatocellular carcinoma and other cancers with frequent DLC1 inactivation, and can be employed in high-throughput screens, RNA-seq, and apoptosis assays such as Annexin V staining. For further details, please contact Ascent Research.
